Atomwise develops artificial intelligence systems using powerful deep learning algorithms and supercomputers for drug discovery.
Atomwise has a patent of the first deep learning technology for structure-based small molecule drug discovery. Using AI, the platform uses millions of data points and thousands of protein structures to solve problems that chemists would take hundreds of years to solve.
Atomwise is a partner of the world’s largest pharmaceutical companies, 200+ universities and hospitals in 40 countries that takes part in hundreds of projects every year.
Atomwise has raised $176.6M in funding over 8 funding rounds between 2012 and 2020.